HC Wainwright & Co. Reiterates Buy on Alpine Immune Sciences, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Alpine Immune Sciences (NASDAQ:ALPN) and maintained a price target of $17.
August 31, 2023 | 10:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alpine Immune Sciences (NASDAQ:ALPN) has had its 'Buy' rating reiterated and $17 price target maintained by HC Wainwright & Co.
The reiteration of a 'Buy' rating and maintenance of a $17 price target by HC Wainwright & Co. indicates a positive outlook for Alpine Immune Sciences. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100